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Abstract
Mutations in dystrophin can lead to Duchenne muscular dystrophy or the more mild form of the disease, Becker muscular
dystrophy. The hinge 3 region in the rod domain of dystrophin is particularly prone to deletion mutations. In-frame
deletions of hinge 3 are predicted to lead to BMD, however the severity of disease can vary considerably. Here we
performed extensive structure-function analyses of truncated dystrophins with modified hinges and spectrin-like repeats in
mdx mice. We found that the polyproline site in hinge 2 profoundly influences the functional capacity of a
microdystrophin
DR4-R23/DCT with a large deletion in the hinge 3 region. Inclusion of polyproline in microdystrophin
DR4-R23/DCT
led to small myofibers (12% smaller than wild-type), Achilles myotendinous disruption, ringed fibers, and aberrant
neuromuscular junctions in the mdx gastrocnemius muscles. Replacing hinge 2 of microdystrophin
DR4-R23/DCT with hinge 3
significantly improved the functional capacity to prevent muscle degeneration, increase muscle fiber area, and maintain the
junctions. We conclude that the rigid a-helical structure of the polyproline site significantly impairs the functional capacity
of truncated dystrophins to maintain appropriate connections between the cytoskeleton and extracellular matrix.
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Introduction
Duchenne muscular dystrophy (DMD) is a lethal X-linked
recessive disease caused by mutations in the 2.2 MB dystrophin
gene [1–3]. In skeletal muscle, dystrophin provides a flexible
connection between the cytoskeleton and the dystrophin-
glycoprotein complex at the sarcolemma, myotendinous junction
(MTJ) and neuromuscular junction (NMJ) [4–6]. Mutations that
affect the mechanical integrity of this molecular scaffold render
muscles more susceptible to contraction-induced injury leading to
cycles of necrosis and regeneration [3].
As a general rule, most frame-shift mutations in dystrophin
lead to DMD whereas internal truncations (in-frame deletions)
lead to a milder form of the disease called Becker muscular
dystrophy (BMD) [7–14]. The severity of BMD can also vary
depending on whether a critical region of dystrophin is deleted
and the amount of dystrophin being expressed [7–14]. Dystro-
phin consists of a N-terminal actin-binding domain, a large
central rod domain, a cysteine rich region and a C-terminal
domain (Figure 1A) [15,16]. The central rod domain contains 24
spectrin-like repeats, 4 hinges and a second actin-binding domain
[15–20]. The locus encoding the N-terminal actin-binding
domain and the region near hinge 3 of dystrophin are more
susceptible to deletion mutations [7–13]. In-frame deletions of the
central rod domain typically lead to a mild BMD [8–13].
However, in-frame deletions at the ‘‘hot spot’’ near hinge 3 can
lead to more variable phenotypes [8–13,21].
The role of dystrophin in vivo has been largely defined by the
structure-function relationship of truncated dystrophins in humans
and mice [8–13,22–24]. Rational design of dystrophin mini-genes
has been highly effective in preventing and reversing functional
abnormalities of dystrophic muscles [22–29]. In particular, we
previously developed a microdystrophin (DR4-R23/DCT; defined
as those with 4 or fewer spectrin-like repeats [24]) that
accommodates the limited cloning capacity of recombinant
adeno-associated viral vectors (rAAV) [24]. Intravenous injection
of rAAV vectors pseudotyped with serotype 6 capsid (rAAV6)
expressing microdystrophin
DR4-R23/DCT can prevent and reverse
most aspects of dystrophic pathology in mdx muscles [24,28,30–
35]. Microdystrophin
DR4-R23/DCT also significantly protects mus-
cles from contraction-induced injury [24,28,30–35].
While the microdystrophin
DR4-R23 transgene provides a clear
benefit to dystrophic muscles [24], more detailed analyses have
revealed a potentially serious abnormality in some muscle groups.
The microdystrophin
DR4-R23/mdx transgenic mice have chronic
Achilles myotendinous strain injury, which leads to the formation
of ringed fibers and fragmentation of the neuromuscular junctions
[33,36]. In the present study we examined whether the domain
composition or the small size of microdystrophin
DR4-R23/DCT led
to this myopathy in mdx mice. We found that the hinge regions of
PLoS Genetics | www.plosgenetics.org 1 May 2010 | Volume 6 | Issue 5 | e1000958microdystrophin, rather than its small size can profoundly
influence skeletal muscle maintenance, maturation and structure.
Results
Dystrophin hinge domains influence the maintenance
and maturation of skeletal muscles
We initially screened several truncated dystrophins and found
that inclusion of hinge 2, but not hinge 3 could lead to the
structural abnormalities we observed in some muscles of the
microdystrophin
DR4-R23 transgenic mice (Text S1; Figures S1, S2,
S3). We subsequently compared the efficacy of two microdystro-
phins that differ only in their inclusion of hinge 2 (microdystro-
phin
DR4-R23/DCT) or hinge 3 (microdystrophin
DH2-R23+H3/DCT)
(Figure 1A) to examine whether the hinge composition of
microdystrophin could influence various aspects of muscle disease.
We administered a sub-optimal dose of 2610
12 vector genomes
of a rAAV6 pseudotyped vector expressing either microdystro-
phin
DR4-R23/DCT or microdystrophin
DH2-R23+H3/DCT intravenously
into 2 week-old mdx
4cv mice. We used a sub-optimal dose of rAAV6-
microdystrophins so that we could examine whether changing the
hinge domain increased or decreased the functional capacity of
microdystrophin. Six months after treatment, both microdystro-
phins were expressed in a similar percentage of gastrocnemius and
tibialis anterior (TA) muscle fibers (ranging from approximately
61% to 71%; P=0.238 when comparing between the micro-
dystrophins; Figure 1B and 1D). Western blots confirmed similar
expression levels of truncated dystrophins in treated gastrocnemius
muscles (Figure 1C). Both microdystrophins restored dystrophin-
associated proteins to the sarcolemma except for nNOS (Text S1;
Figure S4). Microdystrophin
DR4-R23/DCT containing hinge 2
significantly prevented muscle degeneration (,11% central nuclei
for treated muscles verse ,78% for untreated mdx muscles;
P,0.001), and limited the fiber area of skeletal muscles (12%
smaller than wild-type;P,0.05;Figure1E),consistentwith previous
studies [24,32,33]. Microdystrophin
DH2-R23+H3/DCT containing hinge
3 was significantly better able to prevent muscle degeneration (1–2%
central nuclei; P,0.05 compared to microdystrophin
DR4-R23/DCT),
and surprisingly increased average muscle fiber cross sectional area
(34% larger than wild-type; P,0.001; Figure 1E). Thus, replacing
hinge 2 of microdystrophin
DR4-R23/DCT with hinge 3 significantly
improved its capacity to prevent muscle degeneration and promote
skeletal muscle maturation.
Dystrophin hinge domains influence myotendinous
junction injury and formation of ringed fibers
The tendon extends deep folds into wild-type skeletal muscles to
minimize membrane stress under shear (Figure 2)[37]. Most of the
foldsinthemdxjunctionsdidnotextendasfarintothegastrocnemius
muscles (Figure 2). rAAV6-microdystrophin
DR4-R23/DCT severely
disruptedthe Achilles myotendinous junctions inmdxmice. Many of
the junctional folds were missing and myofibril degeneration was
evident (Figure 2). Approximately 17% of the adjoining mdx
gastrocnemius muscles had ringed fibers. In contrast, rAAV6-
microdystrophin
DH2-R23+H3/DCT with hinge 3 retained the normal
architecture of the Achilles myotendinous junction and we found no
ringed fibers in the adjoining gastrocnemius muscles (Figure 2).
Thus, the hinge domains influenced whether microdystrophin was
capable of maintaining the myotendinous junction and myofibril
structure in mdx gastrocnemius muscles.
Dystrophin hinge domains influence neuromuscular
synapse structure
We also examined neuromuscular synapses in mdx mice treated
with rAAV6-microdystrophins. Most neuromuscular synapses in
wild-type mice (,97%) form a continuous tertiary structure as
shown by staining whole muscle fibers with a-bungarotoxin
(Figure 3A). Neuromuscular synapses in mdx mice begin to
fragment temporally coincident with muscle degeneration [38].
Approximately 89% of neuromuscular synapses were fragmented
in the gastrocnemius muscles of mdx mice (Figure 3B). We had
previously shown that the neuromuscular synapses in transgenic
microdystrophin
DR4-R23/mdx gastrocnemius muscles fragmented
temporally coincident with the formation of ringed fibers [36]. In the
present study we found that rAAV6- microdystrophin
DR4-R23/DCT
containing hinge 2 maintained continuous synapses in only 46% of
the mdx gastrocnemius muscles (Figure 3A and 3B). In contrast,
approximately 84% of synapses were continuous in mdx gastrocne-
mius muscles treated with rAAV6-microdystrophin
DH2-R23+H3/DCT
containing hinge 3 (Figure 3A and 3B).
Neuromuscular synapses also contain folds in the postsynaptic
membrane that align directly adjacent to vesicle release sites (active
zones) in the pre-synaptic nerve terminal (arrows; Figure 3C). The
number of synaptic folds in mdx mice was significantly reduced
compared to wild-type (P,0.01; Figure 3C and 3D) as previously
described [4,39]. The number of folds was restored in micro-
dystrophin
DR4-R23/DCT and microdystrophin
DH2-R23+H3/DCT treated
muscles (Figure 3C and 3D). The synaptic folds extended
significantly further into microdystrophin
DR4-R23/DCT treated mdx
muscles compared to wild-type muscles (P,0.001; Figure 3C and
3E), as previously described in transgenic microdystrophin
DR4-R23/
mdxmice[36].Incontrast,thenumberandlengthofsynapticfoldsin
microdystrophin
DH2-R23+H3/DCT treated mdx muscles was similar to
wild-type (Figure 3C–3E). Thus, microdystrophin
DH2-R23+H3/DCT
containing hinge 3 can maintain the structure of neuromuscular
junctions in mdx muscles.
Mechanical properties of muscles expressing
microdystrophins with either hinge 2 or hinge 3
Contraction-induced injury can initiate muscle degeneration in
mdx mice [40]. Skeletal muscles from mdx mice have a lower force
Author Summary
Dystrophin functions like a large molecular spring between
the muscle cytoskeleton and the extracellular matrix in
order to protect the membrane from contraction-induced
injury. Mutations in dystrophin can lead to a severe muscle
wasting disease called Duchenne muscular dystrophy
(DMD) in young boys. DMD patients are typically
wheelchair bound by 9–13 years of age and die at
approximately 30 years. There are also mutations within
the dystrophin gene that lead to internal truncations of
non-essential regions, such as the internal rod domain that
leads to a mild form of the disease called Becker Muscular
Dystrophy. However, these internal truncations frequently
occur at a ‘‘hot spot’’ within the rod domain where the
resulting disease severity is difficult to predict. Here we
found that consecutive proline residues, that function
much like a molecular ruler, can dramatically influence the
function of these internally truncated dystrophins within
skeletal muscles. Using this information, we designed a
dystrophin mini-gene that can accommodate the limited
packaging size of recombinant adeno-associated virus.
This virus can deliver the dystrophin mini-gene to most
muscles throughout a dystrophic mouse to prevent
muscle degeneration and partially restore muscle function.
Polyproline Influences Dystrophin Function
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susceptible to contraction-induced injury (Figure 4). We found that
sub-optimal doses of both rAAV6-microdystrophin
DR4-R23/DCT and
rAAV6- microdystrophin
DH2-R23+H3/DCT maintained the peak force
producing capacity of mdx gastrocnemius and tibialis anterior
muscles (Figure 4A). Both microdystrophins also significantly
improved the specific force (force per cross sectional area of muscle)
production in mdx muscles (P,0.05; Figure 4B). The specific force
was not restored to wild-type partly because the sub-optimal dose of
rAAV6-microdystrophin did not prevent the pseudo hypertrophy
normally found in mdx muscles (P=0.454 when comparing the
muscle mass between mdx and treated mdx muscles; one-way
Figure 1. The hinge domains of dystrophin influence muscle maturation and maintenance. (A) The molecular structure of truncated
dystrophins (reviewed in: [15]). ABD1 at the N-terminus is composed of two calponin homology domains denoted by the two circles. The central rod
domain contains 24 spectrin-like repeats (R1-24), 4 hinge domains, a 20 amino acid insertion between spectrin-like repeats 15 and 16, and a central
actin-binding domain (ABD2). A cluster of basic repeats forms ABD2 that bind to actin through an electrostatic interaction [20]. The hinge domains
vary in that hinge 2 contains a polyproline site and hinge 4 contains a WW motif that is required for binding to b-dystroglycan [19,68]. The cysteine-
rich region contains two EF hands and a ZZ domain that is also required for binding to b-dystroglycan. The microdystrophins used in this study are
shown below the full-length dystrophin. Microdystrophin
DR4-R23/DCT lacks a large portion of the central rod domain between spectrin-like repeats 4
and 23 and also lacks the C-terminal domain (DR4-R23/DCT) [24]. Note that microdystrophin
DR4-R23/DCT and microdystrophin
DH2-R23+H3/DCT differ by a
single hinge domain. (B) Transverse sections of gastrocnemius muscles from wild-type, mdx and mdx mice expressing either microdystro-
phin
DR4-R23/DCT or microdystrophin
DH2-R23+H3/DCT. Scale bar =100 mm. (C) Expression of truncated dystrophins in treated mdx gastrocnemius muscles
was similar. The western blots were performed using frozen muscles extracted from OCT. All lanes were loaded equally as shown by a-sarcomeric
actin. (D) Shown is the mean +/2 S.D. percentage of dystrophin-positive muscle fibers. TA is tibialis anterior. (E) Shown is the mean +/2 S.D. of the
percentage of muscle fibers containing centrally-located nuclei. Microdystrophin
DH2-R23+H3/DCT with hinge 3 was more effective at preventing muscle
degeneration in mdx mice compared to microdystrophin
DR4-R23/DCT with hinge 2. The treated muscles show the mean +/2 SD for dystrophin-positive
fibers only. ***P,0.001 compared to untreated mdx mice.
#P,0.05 compared to microdystrophin
DR4-R23/DCT treated mdx muscles. (F) Hinge regions
of dystrophin influence muscle fiber cross-sectional area. Shown is the mean +/2 distribution (25th and 75th percentile (box) in addition to the
farthest (whiskers) area of muscle fibers. *P,0.05 and ***P,0.001 compared to wild-type.
doi:10.1371/journal.pgen.1000958.g001
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limb muscles from contraction-induced injury (P,0.001; Figure 4C
and 4D). However, we found no significant difference between the
peak force, specific force or protection from contraction-induced
injury when comparing between the two microdystrophins with
either hinge 2 or hinge 3.
Polyproline in hinge 2 influences the pathology of
skeletal muscle fibers
Together, our results suggested that the structural abnormal-
ities observed in some treated mdx muscles could be traced to the
presence of hinge 2 within the microdystrophin. We next
examined the molecular composition of the hinges to define
Figure 2. The hinge domains of dystrophin influence myotendinous junction structure and ringed fiber formation. Shown are
electron microscopy images of longitudinal sections of the Achilles myotendinous junctions in addition to transverse sections of gastrocnemius
muscles. Note that expression of microdystrophin disrupted the myotendinous junctions and led to formation of ringed fibers (arrow). Scale bar =5 mm
for myotendinous junctions and 2 mm for transverse sections of gastrocnemius muscles.
doi:10.1371/journal.pgen.1000958.g002
Figure 3. The hinge domains of dystrophin influence the structure of neuromuscular synapses. (A) Topographic view of AChR clusters
stained with a-bungarotoxin. Scale bar =10 mm. (B) Graph shows mean +/2 SD percentage of continuous synapses. Significant difference to mdx
***P,0.001. Significant difference to microdystrophin
DR4-R23/DCT/mdx mice
###P,0.001. (C) Ultrastructure of neuromuscular synapses from wild-
type, mdx and mdx gastrocnemius muscles expressing microdystrophin
DR4-R23/DCT and microdystrophin
DH2-R23/DCT+H3. Note that synaptic folding is
reduced in mdx mice and increased in rAAV6-microdystrophin
DR4-R23/DCT treated muscles (arrows). Scale bar =0.5 mm. (D) The graph shows the mean
+/2 SD number of folds per mm of postsynaptic membrane juxtaposed to the presynaptic cleft. Significant difference compared to wild-type
**P,0.01. (E) The mean +/2 SD depth of the folds was significantly increased in mdx muscles treated with rAAV6-microdystrophin
DR4-R23/DCT
(***P,0.001).
doi:10.1371/journal.pgen.1000958.g003
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defined as such because of the higher concentration of proline
residues, which function to limit the continuation of the a-helical
coiled-coils of the spectrin-like repeats through the entire length
of the dystrophin rod domain [19]. Both hinge 2 and hinge 3
have six proline residues and the lengths of these hinges are
similar [19]. We hypothesized that the placement of the prolines
most likely results in their different functions [5,19]. Hinge 2 has
5 consecutive proline residues (polyproline; Figure 5A) whereas
the proline residues in hinge 3 are more evenly distributed
throughout the hinge [19]. Polyproline residues are thought
to have their own defined rigid helical structure [41,42], and
this could affect the functional capacity of microdystro-
phin
DR4-R23/DCT.
To test this hypothesis we compared muscles expressing the
original microdystrophin
DR4-R23/DCT with a newly developed
microdystrophin
DpolyP/DR4-R23/DCT that lacks the polyproline site
in hinge 2 (Figure 5A). We delivered 6610
10 vg of each
microdystrophin into mdx gastrocnemius muscles at 2 days of
age and examined the mice 7 weeks after treatment. Both
microdystrophins were expressed in a similar percentage of muscle
fibers (Figure 5B; 59–68%), and were expressed at similar levels
(Figure 5C). Each microdystrophin significantly reduced muscle
fiber degeneration (Figure 5D). As expected, the original
microdystrophin
DR4-R23/DCT limited muscle fiber cross-sectional
area (Figure 5E), was associated with disrupted myotendinous
junctions (Figure 5F), led to the formation of ringed fibers
(Figure 5F), and perturbed neuromuscular junctions (Figure 5G–
5I). In contrast, the mdx muscles treated with microdystro-
phin
DpolyP/DR4-R23/DCT did not show any abnormalities in muscle
fiber maturation or structure (Figure 5). Thus, the presence of this
polyproline site in hinge 2 of microdystrophin
DR4-R23/DCT
prevented the appropriate integration of muscles into the nerve-
tendon environment.
Discussion
Most gene therapy strategies for DMD require the generation
of highly functional truncated dystrophins. rAAV is an efficient
and safe vector for systemically delivering truncated dystrophins
to striated muscles to prevent muscle degeneration in animal
models of DMD ([28]; reviewed in [43]). We had previously
generated a microdystrophin
DR4-R23 that was highly capable of
mitigating muscle degeneration and improving the mechanical
function of mdx skeletal muscles [24,28]. However, the micro-
dystrophin
DR4-R23 transgene leads to chronic strain injury at the
Achilles myotendinous junction [33]. This led to the formation of
ringed fibers that function to protect skeletal muscles from
contraction-induced injury, even better than wild-type mice [33].
The formation of the rings led to fragmentation of the
neuromuscular junctions [36]. Other effects of the transgene
included smaller muscle fibers [24], and increased length of
synaptic folds [36]. Here we found that each of these phenotypic
changes was recapitulated in mdx gastrocnemius muscles treated
with rAAV6-microdystrophin
DR4-R23/DCT. A screen of several
newly developed dystrophin mini-genes revealed that the hinge 2
region influenced the functional capacity of microdystro-
phin
DR4-R23/DCT. Replacing hinge 2 with hinge 3 led to several
Figure 4. Microdystrophins significantly improve the mechanical properties of mdx hind limb muscles. (A) Graph shows the mean +/2
S.D. peak force. *P,0.05 and **P,0.01 compared to wild-type.
#P,0.05 and
###P,0.001 compared to mdx. (B) Graph shows the mean +/2 S.D.
specific force. ***P,0.001 compared to wild-type.
#P,0.05 and
##P,0.01 compared to mdx. The contractile performance of (C) gastrocnemius
muscles and (D) tibialis anterior muscles immediately prior to increasing length changes during maximal force production. Bars represent the mean
+/2 S.D. percentage of the initial optimal muscle contraction. rAAV6-microdystrophin
DR4-R23/DCT treated muscles were significantly (*P,0.05;
**P,0.01; ***P,0.001) protected from contraction-induced injury, as were rAAV6-microdystrophin
DH2-R23/DCT+H3 (
#P,0.05;
##P,0.01;
###P,0.001)
treated muscles when compared to mdx mice.
doi:10.1371/journal.pgen.1000958.g004
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2% central nuclei 6 months post treatment), larger muscle fibers
and normal junctions. Deleting the polyproline site from hinge 2
of microdystrophin
DR4-R23/DCT also prevented these structural
abnormalities.
Mechanical properties of skeletal muscles expressing
microdystrophins
Microdystrophin
DH2-R23+H3/DCT with hinge 3 significantly
increased peak force, specific force and protected muscles from
contraction-induced injury. However, the morphological improve-
Figure 5. Microdystrophin
DR4-R23/DCT did not cause structural abnormalities when the polyproline site was deleted from hinge 2. (A)
The molecular structure of microdystrophins. Below each structure is the amino acid sequence of hinge 2. Note that proline residues are highlighted
in red and that microdystrophin
DPolyP/DR4-R23/DCT lacks the polyproline site. (B) Transverse sections of gastrocnemius muscles from mdx mice
expressing microdystrophin
DR4-R23/DCT (top panel) or microdystrophin
DPolyP/DR4-R23/DCT (lower panel). Scale bar =100 mm. (C) Expression of truncated
dystrophins from treated gastrocnemius muscles. The western blots were performed using tissue sections frozen in OCT. (D) Shown is the mean +/2
S.D. percentage of myofibers with centrally-located nuclei. The treated muscles show the mean +/2 SD for dystrophin positive fibers only.
***P,0.001 compared to untreated mdx mice. (E) The polyproline region influenced muscle fiber cross sectional area. Shown is the mean +/2
distribution (25th and 75th percentile (box) in addition to the farthest (whiskers) of muscle fibers. ***P,0.001 compared to wild-type.
##P,0.01
compared to microdystrophin
DR4-R23/DCT. (F) Microdystrophin
DR4-R23/DCT expression led to a disruption of the myotendinous junctions and ringed fiber
formation (arrow; top panels) in mdx gastrocnemius muscles, but not when the polyproline site was deleted (lower panels). Scale bars =2 mm. (G)
Electron microscopy images of neuromuscular junctions (NMJ) in mdx muscles treated with rAAV6-microdystrophin
DR4-R23/DCT or rAAV6-
microdystrophin
DPolyP/DR4-R23/DCT. Scale bar =1 mm. (H) The graph shows the mean +/2 SD number of folds per mm of postsynaptic membrane
juxtaposed to the presynaptic cleft. (I) Deletion of the polyproline site from microdystrophin
DR4-R23/DCT restored the normal mean +/2 SD length of
synaptic folds (***P,0.001 compared to microdystrophin
DR4-R23/DCT).
doi:10.1371/journal.pgen.1000958.g005
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DH2-R23+H3/DCT treated muscles did not
translate into a functional improvement compared to micrody-
strophin
DR4-R23/DCT treated muscles. This could result from the
molecular and cellular responses to myotendinous strain injury
that help protect the rAAV6-microdystrophin
DR4-R23/DCT treated
muscles from contraction-induced injury [33]. Another possibility
is that the presence of some dystrophin negative fibers masked any
functional difference between the two proteins. The inclusion of
hinge 2 in microdystrophin limited muscle fiber area whereas the
inclusion of hinge 3 increased muscle fiber area (Figure 1). Larger
muscle fibers in microdystrophin
DH2-R23+H3/DCT treated mice
could have two distinct advantages: They could replace some of
the muscle mass lost in advanced stages of disease and they could
be better protected from contraction-induced injury [44].
However, the sub-optimal dose of either rAAV6-microdystrophin
did not prevent the pseudo hypertrophy in mdx mice and no
mechanical advantages could be discerned when comparing
treatments. Saturating levels of rAAV6-microdystrophins or
transgenic mice will most likely be required to detect minor
differences in the mechanical properties of muscles expressing
various truncated dystrophins.
How does polyproline influence the functional capacity
of truncated dystrophins?
Our most effective truncated dystrophins developed for gene
therapy have been designed to maximize functional interactions
between specific spectrin-like repeats and hinge domains. This
design has been influenced by genetic studies in mice and man as
well as biophysical studies in vitro on the structure, folding and
physical properties of both individual and tandemly expressed
spectrin-like repeats and hinge domains [24,45–52]. Individual
spectrin-like repeats are not all interchangeable, and ones adjacent
to hinges have distinct properties from those flanked by other
spectrin-like repeats [21,24,47,51,52]. Also, spectrin-like repeats
rarely function as isolated units [15,24,50–53]. Instead, they
appear to fold into nested domains interrupted by various
insertions (hinges) that disrupt the uniformity and rigidity of the
spectrin-like repeat rod domain [24,45–48,53–55]. These inter-
ruptions appear important for the elastic and flexible structure that
dystrophin requires in its role as a force transducer and shock
absorber in muscle [56–59]. Our studies suggest that the most
functional truncations of dystrophin retain a central hinge domain
that is flanked by spectrin-like repeats found adjacent to a hinge in
the wild-type dystrophin [24]. Disruption of this linkage could
influence protein folding, stability and function leading to the
variable phenotypes in patients associated with deletions at or near
hinge 3, which is encoded on exons 50–51 [21].
Individual spectrin-like repeats are composed of 3 helical
domains connected by non-helical linkers, which fold into a triple
helical coiled coil structure (Figure 5A; [45,47]). The linker regions
between discreet repeats are also typically short and relatively
unstructured to allow a smooth connection between the third helix
of a preceding repeat and the first helix of the next repeat
(Figure 6A). However, hinge domains interrupt the nested nature of
adjacent spectrin-like repeats and allow more flexibility in the rod
domain (Figure 6B). This degree of flexibility appears to be
significantly different when hinge 2 or hinge 3 is present. While both
hinges contain 6 prolines, which act to disrupt alpha helical
structures, in hinge 3 they are dispersed whereas 5 of the 6 prolines
in hinge 2 are clustered together (Figure 5A, Figure 6C and 6D;
[10]). Polyproline residues form a rigid a-helix [41,42], much like a
molecularruler [60].Wesuggest that the locationofthispolyproline
sequence within a highly truncated rod domain induces a severe
structural disruption that can affect the ability of dystrophin to form
a mechanically flexible connection between F-actin and b-
dystroglycan. Spectrin-likerepeats 1-3 have beenshown to associate
with the sarcolemmal membrane, while the WW domain in hinge 4
forms a critical portion of the b-dystroglycan binding domain
[45,61]. A rigid rod domain induced by polyproline in hinge 2 may
directly impair the ability of microdystrophin to form a flexible
interaction with either or both of these structures (Figure 6C). In
contrast, when hinge 2 is present in full-length dystrophin, a
significantly greater number of spectrin-like repeats are present
between the hinge andthe b-dystroglycan bindingdomain, allowing
greater flexibility in the overall structure.
It is difficult to predict the function of the polyproline site from
patients with in frame deletions of exon 17 (hinge 2) of dystrophin.
The described deletions (Leiden Muscular Dystrophy Pages)
usually encompass larger regions of dystrophin than the polypro-
line site and it is not clear how these deletions affect protein
stability. Our finding that hinge 3 microdystrophin can prevent
muscle degeneration suggests that the polyproline site is not a
necessary component of dystrophin, similar to previous reports on
longer forms of truncated dystrophins [24,62].
Flanigan et. al., 2009 has proposed that approximately 62% of
all DMD patients could be treated with oligonucleotides that skip
exons 45–55 (from spectrin-like repeat 18–22)[14]. This would
create a truncated dystrophin that contains hinge 2 but not hinge
3, similar to, but much larger than our microdystrophin
DR4-R23
transgene. It will therefore be of interest to determine whether the
polyproline site in hinge 2 can influence the functional capacity of
larger, truncated dystrophins. It will also be of interest to examine
whether the polyproline site affects the functional capacity of
truncated utrophin constructs that are designed for gene therapy
of DMD [63,64].
Materials and Methods
Mice and ethics statement
We utilized C57Bl/10 wild-type mice and mdx
4cv mice. All
experiments are in accordance with the institution of animal care
and use committee (IACUC) of the University Of Washington.
Generation of constructs
The expression vector CMV-DR4-R23/DCT which uses the
cytomegalovirus immediate early promoter and enhancer to drive
expression of a microdystrophin cDNA was generated as
previously described [32]. We generated the DH2-R24/DCT,
DR2-R23+R18-H3/DCT, DH2-R23+H3/DCT and DPolyP/
DR4-R23/DCT constructs using recombination PCR with
CMV-DR4-R23/DCT as the template [65]. The primers used
to generate DH2-R24/DCT, DR2-R23+R18-H3/DCT, DH2-
R23+H3/DCT and DPolyP/DR4-R23/DCT are found in Table
S1. The resulting expression vectors were sequenced and co-
transfected with the pDGM6 packaging plasmid into HEK293
cells to generate recombinant AAV vectors comprising serotype 6
capsids that were harvested, purified, and quantitated as described
previously [29]. The resulting titer was determined by comparison
to previously known concentrations of rAAV6-CMV-lacZ and
DR4-R23/DCT by Southern analyses with a probe to the CMV
promoter. The rAAV6-microdystrophins were delivered intrave-
nously by tail vein injection at two weeks of age or directly into the
mdx gastrocnemius muscles at 2 days of age while the mice were
anaesthetized.
Gross muscle morphology and morphometry
Gross muscle morphology was analyzed as previously described
[24,32]. Primary antibodies included the N-terminus of dystrophin
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University of Washington), mouse monoclonal anti-a-dystrobrevin
(Transduction laboratories; 1:200), rabbit polyclonal anti-Syn17
(a-syntrophin; 1:200; [66]), rabbit polyclonal anti-nNOS (Alexis;
1:200). Secondary antibodies included Alexa 488, Alexa 594
rabbit polyclonal or Alexa 488 mouse monoclonal secondary
antibodies (Molecular Probes; 1:800). The sections were mounted
in anti-fade mounting media containing DAPI (Vector Labs).
Fluorescent sections were imaged using a Nikon eclipse E1000
fluorescent microscope (Nikon; NY) and captured using a
DeltaVision fluorescence microscope. Muscle fiber areas were
quantified using Image J (NIH).
Immunoblotting
For immunoblots, n=4 gastrocnemius muscles from mdx mice
and mdx mice treated with rAAV6-microdystrophin
DR4-R23/DCT or
rAAV6-microdystrophin
DH2-R23+H3/DCT were thawed from OCT
blocks and placed into extract buffer (50 mM Tris-HCl, 150 mM
NaCl, 0.2% sodium dodecyl sulfate, 10% glycerol, 24 mM Na
Deoxycholate, 1% NP40, 47.6 mM Na Fluoride, 200 mM Na
orthovanadate, Roche). Protein concentrations were determined
by Coomassie Plus Bradford Assay (Peirce). Equal amounts of
protein (15 mg) were resolved on a 4–12% SDS polyacrylamide
gel. The blots were incubated in rabbit polyclonal antibodies to
dystrophin (1:500; kind gift from James Ervasti, University of
Minnesota) and mouse monoclonal antibodies to a-sarcomeric
actin (1:500; SIGMA).
We also performed immunoblots on frozen tissue sections from
n=4 gastrocnemius muscles treated with rAAV6-microdystro-
phin
DR4-R23/DCT and microdystrophin
DPolyP/DR4-R23/DCT as pre-
viously described [67], with minor modifications. Briefly, we cut
twenty-five 20 mm sections and diluted the sections into 200 ml
lysis buffer (4% SDS, 25 mM Tris pH 8.8, 40% glycerol, 0.5 M
phenylmethylsulfonyl fluoride, 100 mM dithiothreitol and bromo-
phenol blue). Samples were briefly sonicated (10 sec at 4uC),
heated to 95uC for 5 minutes, centrifuged for 5 minutes at
13,2006g and electrophoresed on a 4–12% SDS-polyacrylamide
gel. The blots were incubated in primary rabbit polyclonal
antibody against the N-terminus of dystrophin (1:500; kind gift
from James Ervasti, University of Minnesota). All blots were
developed with ECL Plus (Pierce) and scanned with the Storm 860
imaging system (Amersham Biosciences).
Electron microscopy
Electron microscopy was performed as previously described
[33]. The junctional fold number and lengths were measured from
n=4 mice at 6 months of age using Image J (NIH) and compared
using Students t-test (Prism). The counts represent the fold
numbers and lengths from all fibers (dystrophin positive and
negative).
Quantitation of ringed fibers
We quantitated the number of ringed myofibers in EM images
and thick (1 mm) toluidine blue sections from at least 4 animals per
group. At least 300 muscle fibers from n=4 gastrocnemius
muscles were examined from wild-type, mdx
4cv and mdx
4cv mice
expressing the various microdystrophins.
Quantification of neuromuscular synapses
Neuromuscular synapses were analyzed in whole mount
immunofluorescence stained muscles and quantitated as previously
described [36]. The acetylcholine receptor clusters were stained
with TRITC conjugated a-bungarotoxin (aBTX; 1:800; Molec-
ular Probes). Synapses were classified as continuous if they
presented with 3 or less continuous regions of AChR clustering
and discontinuous if they presented with more than 3 regions of
Figure 6. Predicted nested structure of specific dystrophin spectrin-like repeats relevant to microdystrophins and how they
interact with hinge domains. (A) Predicted structure of 3 nested repeats [15]. Each repeat is composed of 3 helical domains (a, b, c) connected by
non-helical linkers. The triple helical coiled-coil repeat structure is formed by helices b and c of the preceding repeat interfacing with the N-terminal
helix a’ from the following repeat. The helices a and b fold together into a long repeat, while helix c folds into the short repeat. (B) In dystrophin, the
repeat domains are interrupted by hinge 2 (between repeats 3 and 4) and by hinge 3 (Repeats19 and 20). Shown is the predicted structure of the
repeat 19-hinge 3-repeat 20 domain in full-length dystrophin. (C) The hinge 2-microdystrophin induces an unusual structural alteration that disrupts
the normal connection between adjacent repeats. (D) In contrast, use of hinge 3 generates a similar structure as in (B) except that hinge 3 joins to
repeats 3 and 24 rather than repeats 19 and 20.
doi:10.1371/journal.pgen.1000958.g006
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treated and untreated gastrocnemius skeletal muscle fibers from
n=4 mice. The counts in treated muscles include both dystrophin
positive and negative fibers. We compared the proportion of
continuous synapses using a Students t-test.
Muscle physiology
Muscle physiology was performed as previously described for
tibialis anterior [29] and gastrocnemius [33] muscles. We
examined six-month-old wild-type, mdx, and mdx mice treated
with rAAV6-microdystrophin
DR4-R23/DCT or rAAV6-microdystro-
phin
DH2-R23+H3/DCT (n=5).
Supporting Information
Figure S1 The molecular structure of truncated dystrophins.
ABD1 at the N-terminus is composed of two calponin homology
domains denoted by the two circles. The central rod domain
contains 24 spectrin-like repeats (R1-24), 4 hinge domains, a 20
amino acid insertion between spectrin repeats 15 and 16, and a
central actin-binding domain (ABD2). A cluster of basic repeats
forms ABD2 that bind to actin through an electrostatic interaction.
The hinge domains vary in that hinge 2 contains a polyproline site
and hinge 4 contains a WW motif that is required for binding to
dystroglycan. The cysteine rich region contains two EF hands and
a ZZ domain that is also required for binding to dystroglycan. The
microdystrophins used in this study are shown below the full-
length dystrophin. Microdystrophin
DR4-R23/DCT has a large
portion of the central rod domain missing between spectrin
repeats 4 and 23 and also lacks the C-terminal domain (DR4-R23/
DCT). Note that microdystrophin
DR4-R23/DCT and microdystro-
phin
DH2-R23+H3/DCT differ by a single hinge domain.
Found at: doi:10.1371/journal.pgen.1000958.s001 (9.25 MB TIF)
Figure S2 Expression of various microdystrophins in the
gastrocnemius muscles of mdx mice significantly reduced the
percentage of central nuclei. (A) Mean +/2 S.D. of the percentage
of muscle fibers expressing the microdystrophins. (B) Mean +/2
S.D. percentage of central nuclei. ***P,0.001 compared to mdx
mice.
Found at: doi:10.1371/journal.pgen.1000958.s002 (3.06 MB TIF)
Figure S3 Microdystrophin
DR4-R23/DCT leads to ringed fibers
when hinge 2 is present. Shown are transverse sections from wild-
type, mdx and mdx gastrocnemius muscles expressing various
microdystrophins. Arrows point to ringed fibers in mdx muscles
treated with microdystrophin
DR4-R23/DCT. Scale bars =2 mm for
electron microscopy images and 50 mm for the other images.
Found at: doi:10.1371/journal.pgen.1000958.s003 (9.93 MB TIF)
Figure S4 The hinge domains of dystrophin do not influence
restoration of the dystrophin glycoprotein complex. Shown is the
localization of dystrophin-associated proteins in transverse sections
from wild-type, mdx and mdx mice treated with rAAV6-micro-
dystrophin
DR4-R23/DCT or rAAV6-microdystrophin
DH2-R23/DCT+H3.
Scale bar =200 mm.
Found at: doi:10.1371/journal.pgen.1000958.s004 (10.31 MB
TIF)
Table S1 Primers for cloning truncated dystrophin vectors
Found at: doi:10.1371/journal.pgen.1000958.s005 (0.04 MB
DOC)
Text S1 Supporting details for supplemental data.
Found at: doi:10.1371/journal.pgen.1000958.s006 (3.54 MB
DOC)
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